Interferon gamma News and Research

RSS

Deep profiling of SARS-CoV-2 immune response amongst the mildly symptomatic

In a research paper recently uploaded to the medRxiv* preprint server by Capelle et al. (September 2nd, 2021), the immune response of mild and hospitalized COVID-19 patients is compared, finding that early T-cell response is a vital indicator of SARS-CoV-2 disease severity.

15 Sep 2021

Scientists identify potential biomarkers to predict COVID-19 outcomes

A team of scientists from the United States has recently examined the trajectory of early immune biomarkers in response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. They have identified specific plasma proteins that can accurately predict the clinical and virological outcomes in SARS-CoV-2 infected patients. The study is currently available on the medRxiv* preprint server.

31 Aug 2021

MS patients on anti-CD20 therapy have robust T cell responses to SARS-CoV-2 vaccination

Scientists have observed that MS patients exhibit a robust T cell response despite a reduced humoral response to COVID-19 vaccines. Read more here.

27 Aug 2021

Study examines the role of programmed cell death ligands in skin immune responses

T cells are a crucial part of the human adaptive immune system. In response to a foreign invader in the body, various subsets of T cells are responsible for several functions that include killing infected cells and secreting signaling molecules called cytokines that tell other immune cells where to go and what to do.

29 Jul 2021

Clinical trials during a pandemic – lessons from COVID-19

In this interview, Dr. Benedicte Roquebert, Dr. Stephanie Haim-Boukobza and Dr. Souad Mehlal discuss how COVID-19 has resulted in new ways to think about clinical trials during a pandemic.

From Cerba Research 23 Jul 2021

Study sheds light on immune processes involved in long COVID

Researchers in the United States have provided important insights into the immune processes that may be associated with post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection – also referred to as long COVID (coronavirus disease 2019).

12 Jul 2021

Scientists discover potential marker for the success of immunotherapy in lung cancer patients

Lung cancer has the highest mortality rate of all cancers, and treatment options are extremely limited, especially for patients with oncogenic mutations in the KRAS gene.

8 Jul 2021

Oxford-AstraZeneca COVID-19 vaccine induces robust T cell-based immunity

A recent study conducted by an international team of scientists has revealed that the Oxford-AstraZeneca coronavirus disease 2019 (COVID-19) vaccine, AZD1222, is capable of inducing strong spike-specific CD4+ T cell helper type 1 (Th1) and CD8+ T-cell responses in vaccinated individuals. A detailed description of AZD1222-induced cellular immunity is currently available on the medRxiv* preprint server.

28 Jun 2021

Standardizable assay detects T cell responses to SARS-CoV-2 infection

Researchers in the UK have developed a high-throughput standardizable assay that accurately detects T cell responses to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

6 Jun 2021

Maternal SARS-CoV-2 infection imprints immune response in the newborn

A new bioRxiv* preprint reports the immunological footprint in the newborn left by maternal infection with SARS-CoV-2 during pregnancy.

4 Jun 2021

An exploratory study of T-cell and antibody responses after COVID-19 mRNA vaccination

Recent COVID-19 investigations have found that up to half of immunocompromised individuals struggle to produce antibodies after receiving their severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccinations.

26 May 2021

Can a single BNT162b2 vaccine dose confer protective immunity against SARS-CoV-2 variants?

A team of researchers in Germany aimed to determine if the Pfizer-BioNTech vaccine mRNA vaccine (also known as the BNT162b2 vaccine) induces robust antibody responses against emergent SARS-CoV-2 variants, including the United Kingdom (or B1.1.7) variant; the South African (or B.1.351) variant; and the Brazilian (or P.1) variant.

21 Apr 2021

Single dose of Oxford–AstraZeneca COVID vaccine shown to be more immunogenic than natural infection

By investigating antibody and T cell responses to a single dose of the Oxford–AstraZeneca COVID-19 vaccine, researchers from Sri Lanka and the United Kingdom have found that more than 90% of vaccinated individuals produced an adequate amount of antibodies after receiving only one dose of the vaccine – irrespective of their age and gender.

16 Apr 2021

GBP5 protein may play a key role in suppressing inflammation in rheumatoid arthritis

New research led by scientists at Washington State University has found that a protein known as GBP5 appears to play a key role in suppressing inflammation in rheumatoid arthritis, a potentially debilitating disease in which the immune system mistakenly attacks the body's own joint tissues.

29 Mar 2021

DNMT3a plays a key role in regulating HSC responses to infections

Humans are born with tens of thousands of hematopoietic stem cells (HSCs) that collectively ensure lifelong production of blood and immune cells that protect us from infections.

26 Mar 2021

Study characterizes shifting neoantigen burden between primary and metastatic tumors within HNSCC

Oncotarget published "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma" which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.

18 Mar 2021

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

Study reveals how cancer cells escape death by lymphocytes

Immunotherapy continues to show exciting promise in more effectively combating several tumor types. Many current strategies focus on ensuring the efficient delivery of active cytotoxic cells directly to tumors.

24 Feb 2021

Probiotics may be beneficial in COVID-19 treatment

A new study explores the role of common probiotics in managing the disease, which could prove to be of great value, given the emergence of new variants and the broad spectrum of clinical disease in COVID-19.

17 Feb 2021

Study shows how SARS-CoV-2 uses an immune system defense for replication

The immune system actually wants to fight SARS-CoV-2 with antiviral signaling molecules. But a research team from Charité and MDC has now shown how such a signaling molecule can promote the replication of the virus. The results have been published in the journal EMBO Molecular Medicine.